Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(11 sites)
France
Institut Bergonié, Bordeaux Centre François Baclesse, Caen Centre Jean Perrin, Clermont-Ferrand Centre Georges-François Leclerc, Dijon Institut régional du Cancer de Montpellier, Montpellier Centre Antoine Lacassagne, Nice Institut Jean Godinot, Reims Centre Henri Becquerel, Rouen Institut de cancérologie Strasbourg Europe - ICANS, Strasbourg Gustave Roussy, Villejuif Last updated November 2025